Clinical Trial Update: Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is evaluating nebivolol as a disease-modifying treatment for diabetic neuropathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• Nebivolol (Nebivolol)

Snippet

Sponsor: St. John's Research Institute | Conditions: Diabetic Neuropathy Peripheral | Phase 2, Phase 3 | Status: RECRUITING